Zobrazeno 71 - 80
of 295
pro vyhledávání: ''
Autor:
Vassiliki Kyriakou, Petros Kopterides, George Arapogiannis, Christos Kosmas, E. Patsouris, Thomas G. Papathomas, Haralambos Zorzos, Nikolaos Kavantzas, Panagiotis Gouveris, Nicolas Tsavaris, Andreas C. Lazaris
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Human DNA topoisomerases I and II (topo-I and -II) are essential for vital cellular processes such as DNA replication, transcription, translation, recombination, and repair. In the present study, we correlate topo-I and -II expression and out
Publikováno v:
Cancer Chemotherapy and Pharmacology. 64:73-78
The efficacy and toxicity of combined paclitaxel (PTX) and gemcitabine (GEM) was evaluated as a protocol for first-line chemotherapy in 40 patients with advanced non-small-cell lung cancer (NSCLC).Paclitaxel, 100 mg/m(2), was administered intravenous
Autor:
Jordi Rodon, Chia Chi Lin, Kyriakos P. Papadopoulos, Anthony W. Tolcher, Chris H. Takimoto, Alain C. Mita, Monica M. Mita, I-Tien Yeh, John Sarantopoulos, Helen X. Chen, Amita Patnaik, Janet Dancey, Emiliano Calvo, Theresa Mays, Glenn G. Preston, P. O'Rourke
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:1065-1071
Complex interrelationships exist between the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) receptor pathways. EGFR activation elicits cell proliferation and increased VEGF expression. To maximally inhibit EGFR
Publikováno v:
Cancer Chemotherapy and Pharmacology. 63:381-389
Here we investigate if valproic acid (VA) can enhance the efficacy of commonly used therapies for head and neck squamous cell carcinomas (HNSCC) and the molecular mechanisms that may be related to its anticancer effects.Proliferation and viability of
Autor:
Andrea Mambrini, Rossana Berardi, Vittorio Ferrari, Elena Mazza, Stefano Cascinu, Maurizio Cantore, L. M. Pasetto, Michele Reni, S. Grisanti, Stefano Cereda
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:673-678
Limited information on second-line treatment in patients with pancreatic adenocarcinoma is available. At time of first-line treatment failure, approximately half of the patients are candidates for further treatment.A retrospective review of 183 patie
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:685-688
The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma.Patients received i.v./intrahepatic cisplatin, i.v. gemcitabine, and i.v. treosulfan (
Autor:
S. Gail Eckhardt, Michele Basche, Laura Q M Chow, Cindy L. O'Bryant, S. Grolnic, Lia Gore, Mark Morrow, Mary Kay Schultz
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:631-646
This phase I study was conducted to evaluate the safety, tolerability, pharmacological properties and biological activity of the combination of the lonafarnib, a farnesylproteintransferase (FTPase) inhibitor, with gemcitabine and cisplatin in patient
Autor:
Gerald J. Fetterly, Joel S. Owen, Julie A. Passarell, Kim Stuyckens, Juan Jose Perez-Ruixo, Arturo Soto-Matos, Peter Zannikos, Miguel Angel Izquierdo
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:135-147
Reversible transient elevations in transaminases have been observed after trabectedin administration. A semimechanistic pharmacokinetic and pharmacodynamic (PKPD) model was developed to evaluate the time course of alanine aminotransferase (ALT) eleva
Autor:
Dorthea Horvath, Mark A. Ritter, Edward M. Messing, Paul R. Hutson, Kurt R. Oettel, Jeffrey A. Douglas, George Wilding, Mary Jane Staab, Dona Alberti
Publikováno v:
Cancer Chemotherapy and Pharmacology. 62:373-377
Testosterone administration can lead to increased antipyrine clearance in humans. Medical or surgical castration is a standard treatment of progressive prostate carcinoma, but the effect of the subsequent fall of testosterone concentrations upon drug
Autor:
Wolfgang Hiddemann, Jan Braess, Hansjoerg Eibl, Lars H. Lindner, Michael Fiegl, Matthias Juergens
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Alkylphosphocholines represent a new class of cytostatic drugs with a novel mode of action. Erufosine (ErPC3), the first compound of this class that can be administered intravenously, has recently been shown to be active against human tumor a